Major Histocompatibility Complex 2017; 24 (3): II MHC MHC Precision Medicine HLA personalized medicine precision medicine
|
|
|
- かねろう いちぞの
- 7 years ago
- Views:
Transcription
1 HLA-QC HLA HLA HLA HLA HLA 198 J.J. van Rood MHC Major Histocompatibility Complex Official Journal of Japanese Society for Histocompatibility and Immunogenetics JSHI
2 Major Histocompatibility Complex 2017; 24 (3): II MHC MHC Precision Medicine HLA personalized medicine precision medicine TEL: QCWS HLA II TEL: [email protected] QCWS
3 Major Histocompatibility Complex 2017; 24 (3): MHC
4 30 MHC 2017; 24 (3) [email protected] 1 A4 1 FAX 2 A A FAX
5 MHC 2017; 24 (3) [email protected] 2 3 MHC [email protected] 174
6 Major Histocompatibility Complex 2017; 24 (3): HLA-QC QC HLA-QC 22nd.QCWS QCWS QC DNA HP CD QCWS 2 QCWS QCWS [email protected] 3 QCWS FAX PDF 4 QCWS 6,000 1 [email protected] 5 QCWS QCWS QCWS QCWS QCWS QCWS 2, QCWS 2,000 3 QCWS QCWS
7 MHC 2017; 24 (3) 22 HLA-QC QCWS 22 QCWS QCWS FAX:
8 22 HLA-QC MHC 2017; 24 (3) 22 HLA-QC 1 HLA-QC 2 JSHI QCWS [email protected] 3 1 6, HLA-QC QCWS HLA-QC 22 HLA-QC a DNA-QC a QC b DNA-QC SSP b c QC c þ d þ d e HLA f 1 DNA-QC PCR-SSP SSP DNA b DNA-QC SSP 2 QCWS d e QC QC QC DNA-QC DNA-QC QC 3 QC QC QC 177
9 MHC 2017; 24 (3) 22 HLA-QC QCWS 1 QCWS 8 2 JSHI QCWS [email protected] 3 1 2, HLA-QC QCWS QCWS QCWS
10 22 HLA-QC MHC 2017; 24 (3) QCWS QCWS HLA 1 QCWS QCWS HP QCWS QCWS DNA DNA QCWS ID ID QCWS QCWS HP QCWS QCWS MHC QCWS QCWS QCWS QCWS QCWS QCWS QCWS 179
11 MHC 2017; 24 (3) 22 HLA-QC QCWS ID QCWS 14 QCWS ID QCWS QCWS QCWS DNA-QC -QC 1 6,000 QCWS 2,000 QCWS FAX QCWS FAX [email protected] QCWS 2018 HLA HLA -QC DNA-QC DNA-QC 180
12 22 HLA-QC MHC 2017; 24 (3) QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QC DNA-QC QC QCWS 14thQCWS ID QCWS ID QCWS ID QCWS PDF 181
13 Major Histocompatibility Complex 2017; 24 (3): HLA TEL HLA 2 HLA HLA 3 HLA 182
14 Major Histocompatibility Complex 2017; 24 (3): HLA 1 HLA 2 HLA HLA HLA 1 HLA Certified HLA Technologist JSHI 2 HLA HT/JSHI 2 HLA 1 Certified Director for Histocompatibility JSHI 2 DH/JSHI 3 HLA 2 1 HLA 3 4 HLA HLA HLA 5 HLA HLA 2 HLA
15 MHC 2017; 24 (3) HLA HLA 6 1 HLA HLA 8 HLA HLA 1 HLA HLA 1 15,000 HLA QC 5 6 HLA HLA HLA 184
16 HLA MHC 2017; 24 (3) HLA 10 HLA 2 HLA HLA 11 HLA QC HLA HLA 1 15, HLA QC
17 MHC 2017; 24 (3) HLA , QC , HLA
18 HLA MHC 2017; 24 (3) 17 HLA 2 2 HLA HLA 5, ,000 HLA 18 HLA , , HLA 1 HLA 2 3 HLA
19 MHC 2017; 24 (3) HLA 14 HLA HLA HLA HLA HLA
20 HLA MHC 2017; 24 (3) QC HLA 5 HLA 5 10 HLA 189
21 Major Histocompatibility Complex 2017; 24 (3): HLA HLA HLA HLA 1 HLA HLA HLA
22 30 HLA MHC 2017; 24 (3) , QCWS QC
23 Major Histocompatibility Complex 2017; 24 (3): HLA HLA QC 6 HLA
24 30 MHC 2017; 24 (3) ,
25 Major Histocompatibility Complex 2017; 24 (3): HLA HLA 1 HLA QC 1 HLA QC
26 30 HLA MHC 2017; 24 (3) HLA HLA HLA 15,000 30, HLA A4 195
27 Major Histocompatibility Complex 2017; 24 (3): S17001 S17004 S17002 S17005 S HLA G17001 G17006 G17002 G17007 G17003 G17008 G17004 G17009 G17005 G S02003 S02027 S02007 S02030 S02011 S02031 S02012 S02035 S02019 S12001 S02020 S12002 S
28 MHC 2017; 24 (3) 29 HLA G02002 G02037 G02006 G02038 G02007 G02041 G02011 G02046 G02012 G02058 G02015 G07003 G02020 G07004 G02024 G07007 G02025 G12001 G02028 G12002 G02030 G12006 G
29 Major Histocompatibility Complex 2017; 24 (3): 平成 29 年度認定 HLA 検査技術者認定制度試験問題に関する報告 29 HLA 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA JMS HLA % 94.0% 53.3% 19.6% % 82.1% 47.8% 17.1% % 78.7% 44.8% 19.1% % 94.1% 53.2% 22.9% % 94.1% 53.2% 22.9% % 198
30 29 HLA MHC 2017; 24 (3) 平成 29 年度認定 HLA 検査技術者認定制度試験問題 正解と難問の解説 40% % 5 40% a e a 1, 2 b 2, 3 c 1, 4 d 3, 4 e 1, 5 正解 :c 45.2% b 2 HLA a e a HLA b HLA-B c HLA I d HLA e HLA-DR T 正解 :e 54.8% a 3 a e a 46 b
31 MHC 2017; 24 (3) 29 HLA c HLA 6 d NK KIR ULBP/RAET e 正解 :c 46.4% a, d 4 a e a b c d e 正解 :c 50.0% a 5 HLA I a e 1 MHC MHC 2 HLA-A MHC 3 HLA-B MHC 4 HLA-C MHC 5 HLA-G MHC a 1, 2, 3 b 1, 2, 5 c 1, 4, 5 d 2, 3, 4 e 3, 4, 5 正解 :d 81.0% a 6 HLA a e a HLA dbsnp b HLA DDBJ c HLA IMGT d HLA HapMap e HLA OMIM 正解 :c 63.1% b 7 HLA I a e a 200
32 29 HLA MHC 2017; 24 (3) b c d e 正解 :b 63.1% a 8 HLA HLA a e a HLA-DR B b HLA-A c HLA I NK d HLA MICA T e HLA-G 正解 :c 54.8% d, e 9 HLA I a e a 2 b c 9 10 d e CD8 正解 :a 54.8% c 10 MICA a e a I b KIR c NK T d e microrna 正解 :b 29.8% a, c, d, e MICA NK CD8 T T CD94/NKG2D KIR CD4 T CD94/NKG2D 201
33 MHC 2017; 24 (3) 29 HLA microrna mir b microrna-20a MICA 11 HLA I 2 a e a CD1a b HLA-F c MICA d MR1 e HFE 正解 :c 25.0% b, e MICA HLA a e 1 HLA II 2 HLA I II 3 HLA I II 4 HLA II 5 TAP a 1, 2 b 1, 3 c 2, 3 d 3, 4 e 4, 5 正解 :a 22.6% c TAP HLA I HLA I / HLA II HLA I HLA I 202
34 29 HLA MHC 2017; 24 (3) HLA I II T T 4 13 HLA a e a HLA b c d e HLA 正解 :c 39.3% b T B somatic recombination rearrangement HLA 14 HLA a e a II b I c d TAP1 TAP2 e B II 正解 :d 61.9% a, b 15 NK NKG2 a e a MIC b MIC c III d CD1d e I HLA-A,-B,-C 正解 :a 21.4% b, e MIC NKG2 NKG2D/CD94 DAP10 ULBP RAE-1 NKG2D/CD94 NKG2 203
35 MHC 2017; 24 (3) 29 HLA NKG2A/CD94 NKG2C/CD94 HLA-E DAP12 I CD1d NKT T V I NK KIR KIR3DS KIR DS 16 a e a T Th1/Th2 b c T d NK e B CD40 正解 :c 60.7% e 17 T a e 1 T 2 GVHD T 3 T CD4 T CD8 T 4 HLA T 5 HLA T a 1, 2 b 2, 3 c 2, 5 d 3, 4 e 4, 5 正解 :e 52.4% d 18 T a e MHC I- CD4 4 T MHC- 5 T CD4 CD8 a 1, 2, 3 b 1, 2, 5 c 1, 4, 5 d 2, 3, 4 e 3, 4, 5 正解 :c 66.7% b 19 MHC T TCR TCR T a e a b 204
36 29 HLA MHC 2017; 24 (3) c TCR d T e T 正解 :d 28.9% c, e affinity maturation B somatic hypermutation T TCRT MHC TCR T T T MHC T B 20 a e a b B 1 99% c d 1980 e BCG 正解 :d 82.1% e 21 a e a T b HLA c HLA T d HLA T e 正解 :d 54.2% b, c 22 a e a b c HCV 205
37 MHC 2017; 24 (3) 29 HLA d e 正解 :d 28.9% c HCV HCV 23 a e a b c d e 正解 :b 63.9% d 24 HLA T GVHD a e 1 HLA T a 1, 2, 3 b 2, 3, 4 c 1, 2, 5 d 3, 4, 5 e 2, 4, 5 正解 :b 30.1% a, e HLA GVHD T a e a b One haplotype c HLA HLA 206
38 29 HLA MHC 2017; 24 (3) d e a d 正解 :a 51.2% e 26 a e a CCI 1 3,000/μL b HLA c HLA d HLA HLA ABO e HLA HLA 正解 :d 81.0% a 27 HLA a e a HLA b HLA c HLA d HLA ABO e HLA 正解 :a 65.5% d 28 HLA a e a I HLA-DRB1*15:02 b HLA-DPB1*09:01 c HLA-B*53:01 d HLA-A*27:01 e HLA-DRB1*04:06 正解 :e 31.0% a, c, d HLA I DRB1*04:05 DRB1*15:02 I 207
39 MHC 2017; 24 (3) 29 HLA DRB1*04:05 B*51:01 HLA-B27 B*27:04 B*27:05 B*27:04 B*27:05 B*27:06 B*27:09 29 HLA a e a b c HLA d e 正解 :c 71.1% b 30 HLA a e 1 HLA 2 HLA 3 HLA 4 HLA 5 HLA a 1, 3 b 1, 4 c 2, 3 d 3, 4 e 3, 5 正解 :b 41.0% d 31 HLA a e a b c d e 2 正解 :c 33.7% e genome-wide association study; GWAS HLA HLA HLA 208
40 29 HLA MHC 2017; 24 (3) GWAS 32 a e a ABO O B b Rh Rho(+) Rho(-) c HLA A*24, A*26 A*02, A*24 d TH e MN MN M 正解 :d 83.3% b 33 a e a 2010 b c ES ips d HLA e 正解 :a 30.1% % 21.3% c ,745 47, ES ips HLA 34 ips a e a ips T b ips c ips d ips e ips HLA I 正解 :d 48.2% b 35 a e 209
41 MHC 2017; 24 (3) 29 HLA a MHC b c 1 d e 2000 正解 :d 66.3% a 36 a e a b c d e 正解 :e 16.9% a, c 37 HLA a e 1 HLA DNA 2 LCT HLA 3 SSOP HLA LCT CDC HLA 5 LCT HLA a 1, 2 b 1, 3 c 2, 4 d 2, 5 e 4, 5 正解 :a 56.0% c 38 HLA a e 1 a b a b 2 a a+b a 3 a+b a+c a b c 4 a+b a+c a 5 null allele 210
42 29 HLA MHC 2017; 24 (3) a 1, 2 b 2, 3 c 2, 4 d 3, 5 e 4, 5 正解 :b 41.7% a, c, e 39 a e a b c d HLA e HLA 正解 :d 22.6% b, c HLA HLA 40 HLA a e 1 HLA 2 3 HLA 4 HLA DNA 5 HLA HLA a 1, 2 b 2, 3 c 2, 4 d 3, 4 e 4, 5 正解 :b 61.9% d 41 MLR a e a b c d e 正解 :e 84.5% a 42 MLR a e 211
43 MHC 2017; 24 (3) 29 HLA a MLR CD4 HLA-DR T b MLR T c MLR B d MLR T e MLR T T IL-2 IFN- 正解 :d 45.8% a, b, c, e 43 HLA a e 1 RFLP 2 SSP 3 SBT HLA 4 SSOP 5 SSCP a 1, 2 b 2, 3 c 3, 4 d 3, 5 e 4, 5 正解 :b 75.0% a, c 44 PCR DNA a e a PCR DNA b PCR DNA c DNA A260/A d DNA 260 nm e DNA PCR 正解 :b 77.4% d 45 DNA a e PCR 1 2 a PCR-SSO b PCR-SSP c PCR-SSCP d PCR-RFLP e PCR-SBT 正解 :b 212
44 29 HLA MHC 2017; 24 (3) 70.2% d 46 DNA a e 1 DNA 2 PCR PCR 3 PCR 4 PCR 5 PCR a 1, 3 b 2, 4 c 1, 5 d 3, 4 e 4, 5 正解 :b 94.0% e 47 DTT a e 1 9 μl 50 mm DTT 1 μl 2 1 μl 50 mm DTT 9 μl 3 37 C 30 IgG 4 37 C 30 IgM 5 4 C 30 IgG a 1, 3 b 1, 4 c 2, 3 d 4, 5 e 1, 5 正解 :b 79.8% a 48 a e a SNP b Y c Insertion-deletion d Variable number of tandem repeats VNTR e 正解 :b 40.2% a, c, d 49 a e a CDC HLA b FCXM HLA c FCXM T I B II d LCT I e CDC 213
45 MHC 2017; 24 (3) 29 HLA 正解 :e 59.0% b, c HLA HLA-DRB1*09:01 a e a 0.22 b 0.50 c 0.78 d 1.28 e 2.00 HLA-DRB1*09:01 HLA-DRB1*09: 正解 :e 57.8% b, c 214
46 Major Histocompatibility Complex 2017; 24 (3): J.J. van Rood HLA JJ. van Rood 1973 HLA HLA II van Rood Terasaki van Rood Van Rood Dausset HLA-A2 Rose Payne LA HLA-A HLA Van Rood HLA-B 4a 4b 1) 1959 Vox Sanguinis 2) 39 C van Rood 1970 HLA-D HLA I LCT SD serologically defined HLA-D LD LD LCT LD B van Rood B LCT B HLA I LCT B HLA- I 215
47 MHC 2017; 24 (3) J.J. van Rood 3) HLA-D HLA-D HLA-DR D relatedhla- DQ B HLA II van Rood HLA van Rood 1) J.J. van Rood and A. van Leewen: Leukocyte grouping. A method and its application. J. Clin. Invest. 42: 1382, ) J.J. van Rood, A. van Leewen and J.G. Earnisse: Leucocyte antibodies in sera of pregnant women. Vox Sang. 4: 427, ) J.J. van Rood, A. van Leewen, J.J. Keuning and A.B. van Oud Alblas: The serological recognition of the human MLC determinants using a modified cytotoxicity technique. Tissue Antigens. 5: 73,
48 Major Histocompatibility Complex 2017; 24 (3): HLA JR 350 m TEL A4 1 MS 12 A [email protected] Windows Power Point Mac Power Point * [email protected] 217
49 MHC 2017; 24 (3) XXXX XXXX 1) 2) XXX 1) XX 2) 1 20 mm 25 mm 2 1 Microsoft Word 2 MS Microsoft Excel 2 218
50 219
51 Major Histocompatibility Complex 2017; 24 (3): MHC I MHC ES ips 2006 JST J-STAGE II Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft PowerPoint CDR 2 1 FAX Susceptibility gene for non-obstructive azoospermia in the HLA class II region: correlations with Y chromosome microdeletion and spermatogenesis. Tetsuya Takao 1), Akira Tsujimura 1), Masaharu Sada 2), Reiko Goto 2), Minoru Koga 3), Yasushi Miyagawa 1), Kiyomi Matsumiya 1), Kazuhiko Yamada 2), Shiro Takahara 1) 220
52 MHC 2017; 24 (3) 1) Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan 2) Department of Regenerative Medicine, National Cardiovascular Center, Suita, Osaka, Japan 3) Department of Urology, Osaka Central Hospital, Osaka, Japan FlowPRA HLA 1) 1) 2) 2) 3) 1) 2) 3) words 5 cm, ml, g, Kg, pg, μl, %, C HLA-DRB words 5 3 Introduction Materials and Methods Results Discussion References cm, ml, g, Kg, pg, μl, %, C HLA-DRB1 5 3 LCT Lymphocyte cytotoxicity test et al. 1. Shi Y, Yoshihara F, Nakahama H, et al.: A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis. Regulatory Peptides 127(1 3): , Tongio M, Abbal M, Bignon JD, et al.: ASH#18: HLA-DPB1. Genetic diversity of HLA Functional and Medical Implication (ed. Charron D), Medical and Scientific International Publisher, p , IVIG 1 17(1): 36 40,
53 MHC 2017; 24 (3) 4. 6 Medical View p III Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft PowerPoint CDR 2 1 FAX words IV V J8 MHC [email protected] Tel: Fax: words 400 words words
54 MHC 2017; 24 (3) MHC web 5 MHC PDF MHC HLA HLA HLA HLA URL URL umin.ac.jp/ [email protected] Tel Fax [email protected] FAX [email protected] 223
MHC23-3
Major Histocompatibility Complex 2016; 23 (3): 168 184 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA 11 25 28 10 22 1 4 61 44 6 1 10 11 5 HLA 60 3 27 3 5 9 5 10 19 5 50 22.4 5.9 8.2% 78.7%
日本組織適合性学会誌第23巻2号
Major Histocompatibility Complex 2016; 23 (2): 115 122 HLA 1 1) 1) HLA MHC 1900 HLA HLA キーワード : HLA HLA HLA HLA 2 HLA HLA HLA 3 1 1 HLA HLA 図 1 2016 6 30 2016 8 2 105 0013 1 10 14 3 5 TEL: 03 5776 0048
16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57
Major Histocompatibility Complex 2018; 25 (1): 56 82 抄録集 16 2018 3 3 7 2 4 43 TEL 06 6962 7001 594 1101 840 TEL 0725 56 1220 56 16 MHC 2018; 25 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 3 13:00 13:10 2 3
22 S2-4 教育講演 ( 認定制度講習会 ) 9 月 14( 土 ) 10:00 ~ 12:00 座長 EL-1 EL-2 EL-3 HLA 1,2) 1) 2) HLA HLA 17th QC ワークショップ集会 9 月 14 日 ( 土 ) 13:00 ~ 16:00 タイピング結果解析 1
22 特別講演 Ⅰ 9 月 15 日 ( 日 ) 13:40 ~ 14:40 座長 SL-1 ips 特別講演 Ⅱ( スポンサード ランチ付き ) 9 月 16 日 ( 月 ) 12:00 ~ 13:00 座長 SL-2 HLA シンポジウム Ⅰ 9 月 15 日 ( 日 ) 14:40 ~ 16:40 免疫寛容を誘導する養子免疫療法 : その基礎と臨床応用 座長 S1-1 CREST JST S1-2
provider_020524_2.PDF
1 1 1 2 2 3 (1) 3 (2) 4 (3) 6 7 7 (1) 8 (2) 21 26 27 27 27 28 31 32 32 36 1 1 2 2 (1) 3 3 4 45 (2) 6 7 5 (3) 6 7 8 (1) ii iii iv 8 * 9 10 11 9 12 10 13 14 15 11 16 17 12 13 18 19 20 (2) 14 21 22 23 24
3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: [email protected] 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB
7... 1... 34... 55... 86... 108 15 2003 1 2 3 1 7 pdf 2 8 1996 2-1 9010 5 247 362 4 7 5 4 11 7 22 4 29 45 5 59 6 61 4 63 10 2 820 3 1646 19 1944 1 2 4 11 3 11 22 4 1 340 2 20 3 13 4 450 1 2 3 4 2-2 29
日本組織適合性学会誌第20巻2号
Major Histocompatibility Complex 2013; 20 (2): 121 129 平成 25 年度認定 HLA 検査技術者講習会テキスト HLA 1) 1) HLA HLA HLA PRA Panel reactive antibody DSA Donor specific alloantibody class subclass non-hla HLA キーワード :Human
The Plasma Boundary of Magnetic Fusion Devices
ASAKURA Nobuyuki, Japan Atomic Energy Research Institute, Naka, Ibaraki 311-0193, Japan e-mail: [email protected] The Plasma Boundary of Magnetic Fusion Devices Naka Fusion Research Establishment,
: : BSC - - :
2013 : : BSC - - : - - 58 30 9 70 3 3 1 Association of genetic variants of the α kinase1 gene with myocardial infarction in community dwelling individuals Abstract. ALPK1 ALPK1
Studies on the Antigens Expressed on Trophoblasts Related to MLR-blocking Antibodies Shigenori GOTO Department of Obstetrics and Gynecology, Niigata University School of Medicine (Director: Prof. Shoshichi
:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
…GŒÆ›u››‘KŒâ‚è_cs1.indd
1 1-1 4 1-2 a. b. c. d. e. 1-3 A. 4 B. 3 1-4 a. b. c. d. e. 1-5 1-6 4 1-7 a. b. c. d. e. 1-8 a. b. c. d. e. 1-9 1-10 A. 2 B. C. 1-11 a. / 2 b. / c. / d. / e. / 1-12 a. T b. c. M d. e. 1-13 1-14 1-15 16
...J......1803.QX
5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
Unknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ
22 The 22nd Annual Meeting of the Japan Endocrine Pathology Society 2018 9 21 22 ( ) ( ) ( ) ( ) 22 30 9 21 22 2 22 8 14 4 5 65 12 29 30 9 22 2 Update 2018 2 770-8504 3-18-15 () () JR 30 440 25 4,000 JR
B. 41 II: 2 ;; 4 B [ ] S 1 S 2 S 1 S O S 1 S P 2 3 P P : 2.13:
![B. 41 II: 2 ;; 4 B [ ] S 1 S 2 S 1 S O S 1 S P 2 3 P P : 2.13:](/thumbs/94/118646867.jpg "B. 41 II: 2 ;; 4 B [ ] S 1 S 2 S 1 S O S 1 S P 2 3 P P : 2.13:")
B. 41 II: ;; 4 B [] S 1 S S 1 S.1 O S 1 S 1.13 P 3 P 5 7 P.1:.13: 4 4.14 C d A B x l l d C B 1 l.14: AB A 1 B 0 AB 0 O OP = x P l AP BP AB AP BP 1 (.4)(.5) x l x sin = p l + x x l (.4)(.5) m d A x P O
研修コーナー
l l l l l l l Department of Obstetrics and Gynecology, Fukui Medical University, Fukui l l l l l l µ l β β l α l µ µ l l l l Department of Obstetrics and Gynecology, Gifu University School of Medicine,
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
第1回日本産婦人科
e e TEL045-231-0960 TEL03-3433-1111 3360 4 2 1 1024768 OS RGB -15pins Dsub-15pins PowerPoint PC WindowsXPMicrosoft PowerPoint2002 Microsoft Power Point ( PC ) Windows USB CD-R PC 30 PC PC 36
1997 1... 1... 2... 2... 2... 3... 6... 9... 9... 24... 39... 54... 69 4 1995 1996 A B C D 1 1 2 1 2 3 3 1 1 (1) (2) (3) 32 2 (1) (2) (3) 3 3 4 1 11 12 13 21 22 / / 23 5 4 4 1 9 1997 2 1 1 1 2 1 1 3 2
- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...
取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -
「情報処理」を受講して身に付いたこと
14 1 40 (FD) 4 (1) (2) (3) Word, Excel, PowerPoint (4) 1 Power Point ph p Power Point Word Power Point Power Point Excel Word Excel, PowerPoint Word Excel Word Excel Excel Word Excel Power Point Power
untitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
Journal of the Research Society for 15 years War and Japanese Medicine 1(2) May, 2001
Journal of the Research Society for 15 years War and Japanese Medicine 1(2) May, 2001 Atomic Bomb and Japanese Medicine Soichi IIJIMA ( Key words; Nuclear Weapon, Atomic Bomb, Atomic Injury, Responsibility
64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
PG1501-PJ7816-CO36363-QuantStudio-3-and-5-brochure-Global-J.indd
Applied Biosystems QuantStudio 3 / QuantStudio 5 PCR PCR Applied Biosystems QuantStudio 3 QuantStudio 5 PCR Thermo Fisher Cloud 1 QuantStudio 3 and 5 Real-Time PCR Systems QuantStudio 3 and 5 Real-Time
untitled
http://www.mofa.go.jp/mofaj/toko/visa/index.html http://www.cn.emb-japan.go.jp/jp/01top.htm http://www.shanghai.cn.emb-japan.go.jp/ http://www.guangzhou.cn.emb-japan.go.jp/ http://www.shengyang.cn.emb-japan.go.jp/jp/index.htm
Special IssueManagement principles in the critically ill - Review Case reports et al et al et al et al Nutritional management in critically ill patients Akiko Mano, Emiko Nakataki, Harutaka Yamaguchi,
The Molecular Biology Society of Japan MBSJ NEWS 2013.11 No.106 http://www.mbsj.jp/ 2020 2020 7 2009 4 1 3 2011 1 3 1 2020 XLab 2 3 4 5 XLabExperiment, experience, exciting, expert Eva-Maria Neher 20
22-1.indb
22 1 27 4 20 24 1 2015 3 27 HLA 6 7 26 HLA 8 2015 11 18 HLA-QC 12 DNA Luminex 16 DNA SSO INNO-LiPA 18 DNA SSP 20 DNA SBT 22 FlowPRA 25 LABScreen 26 WAKFlow 28 30 DNA-QC 31 33 QCWS 35 総説 HLA T 37 13 44
steponeplus_bro_f-0210.indd
StepOnePlus / StepOne PCR PCR Applied Biosystems StepOnePlus StepOne PCR 1 Features At A Glance StepOne StepOnePlus / 48 96 FAM/SYBR Green dyes VIC/JOE dyes ROX dyes NED/TAMRA dyes 1. VeriFlex Block StepOnePlus
untitled
11-19 2012 1 2 3 30 2 Key words acupuncture insulated needle cervical sympathetick trunk thermography blood flow of the nasal skin Received September 12, 2011; Accepted November 1, 2011 I 1 2 1954 3 564-0034